Abstract
The addition of clopidogrel to aspirin for patients undergoing percutaneous coronary intervention (PCI) had significantly reduced cardiovascular events. However, despite dual antiplatelet therapy ischaemic events still occur, especially stent thrombosis, which is associated with a high mortality rate. Inter-individual response to clopidogrel is highly variable. It was shown that 4-46% could be considered as high on treatment platelet reactivity (HTPR). Recent studies had demonstrated a relationship between HTPR and ischaemic events in the setting of PCI. Actually the assessment of platelet reactivity in routine practice and its interpretation to make a decision is a debatable issue.
Copyright © 2011 Australasian Society of Cardiac and Thoracic Surgeons and the Cardiac Society of Australia and New Zealand. Published by Elsevier B.V. All rights reserved.
MeSH terms
-
Angioplasty, Balloon, Coronary / methods*
-
Aspirin* / administration & dosage
-
Aspirin* / adverse effects
-
Aspirin* / pharmacokinetics
-
Clopidogrel
-
Combined Modality Therapy
-
Cyclooxygenase Inhibitors / administration & dosage
-
Cyclooxygenase Inhibitors / adverse effects
-
Cyclooxygenase Inhibitors / pharmacokinetics
-
Drug Interactions
-
Drug Resistance
-
Humans
-
Myocardial Ischemia* / blood
-
Myocardial Ischemia* / complications
-
Myocardial Ischemia* / therapy
-
Platelet Activation / drug effects*
-
Platelet Function Tests / methods
-
Purinergic P2Y Receptor Antagonists / administration & dosage
-
Purinergic P2Y Receptor Antagonists / adverse effects
-
Purinergic P2Y Receptor Antagonists / pharmacokinetics
-
Stents
-
Thrombosis / blood
-
Thrombosis / etiology
-
Thrombosis / prevention & control*
-
Ticlopidine / administration & dosage
-
Ticlopidine / adverse effects
-
Ticlopidine / analogs & derivatives*
-
Ticlopidine / pharmacokinetics
-
Treatment Outcome
Substances
-
Cyclooxygenase Inhibitors
-
Purinergic P2Y Receptor Antagonists
-
Clopidogrel
-
Ticlopidine
-
Aspirin